Background: Inadequate treatment of essential hypertension (EH), Obesity, smoking, carbohydrate intolerance, hyperlipidemia, and nephrotox-in-exposure are major confounding factors in progression of Nephroangiosclerosis (N). However, neither the prevalence nor the severity of EH is a reliable predictor of individuals at risk for subsequent nephropathy. Patients and Methods: A 10-years retrospective analysis of 165 adequately treated patients with EH. Results: We observed 2 different renal outcomes. Twenty-three (14%) patients manifested progressive renal disease with > doubling serum creatinine and proteinuria with 3 reaching end-stage kidney disease. At start, biopsy of those patients showed features of “benign” nephroangiosclerosis (N) ± secondary form of focal and segmental glomerulosclerosis (without immune deposits). On the other hand; 142 with similar demographic characteristics, duration and severity of disease did not show significant renal disease on follow up. Conclusion: Induction of progressive N, in patients with EH, is compatible with phenotypic susceptibilities of genetic disorders.
References
[1]
National Institutes of Diabetes and Digestive and Kidney Disease, US Department of Health and Human (2023) US Renal Data System: Annual Data Report.
[2]
Carriazo, S., Vanessa Perez-Gomez, M. and Ortiz, A. (2020) Hypertensive Nephropathy: A Major Roadblock Hindering the Advance of Precision Nephrology. Clinical Kidney Journal, 13, 504-509. https://doi.org/10.1093/ckj/sfaa162
[3]
Weisstuch, J.M. and Dworkin, L.D. (1992) Does Essential Hypertension Cause End-Stage Renal Disease? Kidney International, 36, S33-S37.
[4]
Fogo, A., Breyer, J.A., Smith, M.C., et al. (1997) Accuracy of the Diagnosis of Hypertensive Nephrosclerosis in African Americans: A Report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney International, 51, 244-254. https://doi.org/10.1038/ki.1997.29
[5]
Freedman, B.I., Bowden, D.W., Rich, S.S. and Appel, R.G. (1998) Genetic Initiation of Hypertensive and Diabetic Nephropathy. American Journal of Hypertension, 11, 251-257. https://doi.org/10.1016/S0895-7061(97)00481-0
[6]
Freedman, B.I., Iskandar, S.S. and Appel, R.G. (1995) The Link between Hypertension and Nephrosclerosis. American Journal of Kidney Diseases, 25, 207-221. https://doi.org/10.1016/0272-6386(95)90001-2
[7]
Churchill, P.C., Churchill, M.C., et al. (1997) Genetic Susceptibility to Hypertension-Induced Renal Damage in the Rat. Evidence Based on Kidney-Specific Genome Transfer. Journal of Clinical Investigation, 100, 1373-1382. https://doi.org/10.1172/JCI119657
[8]
Brown, D.M., Provoost, A.P., Daly, M.J., Lander, E.S. and Jacob, H.J. (1996) Renal Disease Susceptibility and Hypertension Are under Independent Genetic Control in the Fawn-Hooded Rat. Nature Genetics, 12, 44-51. https://doi.org/10.1038/ng0196-44
[9]
Lind, J.M. and Chiu, C.L. (2013) Genetic Discoveries in Hypertension: Steps on the Road to Therapeutic Translation. Heart, 99, 1645-1651. https://doi.org/10.1136/heartjnl-2012-302883
[10]
Parsa, A., Kao, W.H., Xie, D., Astor, B., Li, M., et al. (2013) APOL1 Risk Variants, Race, and Progression of Chronic Kidney Diseas. The New England Journal of Medicine, 369, 2183-2196. https://doi.org/10.1056/NEJMoa1310345
[11]
Dubose Jr, T.D. and Santos, R.M. (2012) Vascular Disorders of the Kidney. Goldman’s Cecil Medicine, 24th Edition, Saunders, Singapore. https://doi.org/10.1016/B978-1-4377-1604-7.00127-5
[12]
Kostovska, I., Trajkovska, K.T., et al. (2022) Chapter One—Nephrinuria and podocytopathies, In Makowski, G.S., Ed., Advances in Clinical Chemistry, Vol. 108, Elsevier, 1-36. https://doi.org/10.1016/bs.acc.2021.08.001
